The immunosuppressive TME observed in PLK1-high tumors likely results from complex interactions between tumor cells, immune cells, and chemokine networks, a recognized hallmark of cancer immunotherapy response (Nagarsheth, Wicha & Zou, 2017; Hegde & Chen, 2020). This evidence concerns the gene PLK1 and cancer.